Zhitong Finance App News, Heyu-B (02256.HK) announced that the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) announced that the new drug clinical trial (IND) application for ABSK211, an oral, high-potency, and highly selective small molecule Pan-KRAS inhibitor being developed by the company to treat patients with advanced solid tumors carrying changes in the KRAS gene has been approved by the US Food and Drug Administration (FDA). This is a voluntary announcement issued by the Company. The Group cannot guarantee that ABSK211 will eventually be successfully approved for listing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.